Doctor Anywhere announces US$40.8 mil Series C1 extension round, eyes 'secondary care'
Summary
Returning investors Square Peg and Novo Holdings are among the key investors for the latest round, says Doctor Anywhere in a Dec 7 announcement.A company spokesperson tells The Edge Singapore that the funding is earmarked for expanding its reach in secondary care, building on the integration of Asian Healthcare Specialists (AHS) into the business. While we are unable to discuss our valuation, Doctor Anywhere is maintaining a strong growth trajectory in line with our business targets. The consistent investor confidence evidenced in previous funding rounds further validates our performance.Doctor Anywheres chief executive officer Lim Wai Mun was named EY Entrepreneur of the Year 2022 Singapore (EOY) in November 2022.The 41-year-old told The Edge Singapore last year that he targets to break even by the end of 2023. However, there are no definitive plans for an IPO at present, adds the spokesperson.Founded as a telemedicine platform in 2017, Doctor Anywhere has expanded to become a regional healthcare provider, serving more than 2.5 million users in six Southeast Asian countries.When Covid-19 hit, Doctor Anywhere was the first company in Singapore to launch online-supervised antigen rapid testing (ART), which was opened to the public in January 2020.Weve successfully built a regional digital healthcare ecosystem, delivering accessible and convenient healthcare services through digital innovation, says Lim in the latest announcement. In the next phase of Southeast Asias healthcare evolution, our goal is to empower individuals to take charge of their health and well-being with early detection and preventive measures against chronic illnesses.